Noscapine does not show aneugenic activity in mouse oocytes.
To clarify if noscapine has the ability to induce polyploidy in rodent germ cells in vivo, a cytogenetic study of mouse metaphase II oocytes was conducted after oral treatment with noscapine at the doses of 20, 120 and 400 mg/kg. Plasma concentrations of noscapine were measured by reversed-phase liquid chromatography and UV detection in three satellite groups of mice up to 8 h after administration of these doses. Thus, the relationship of the maximum plasma concentration and the area under the curve (AUC) with that of meiotic progression could be established. Although noscapine was tested at the maximum tolerated dose, no delay of meiotic progression or induction of chromosome malsegregation could be shown as no increase in the frequency of metaphase I-arrested, polyploid or hyperploid oocytes were found. At the highest dose only, noscapine affected the physiology of superovulation as shown by a significant decrease in the mean number of oocytes harvested per female. In view of the large span covered by the doses tested, corresponding to concentrations far above those detected in humans, and the similarity between the pharmacokinetics of noscapine in mouse and humans, it is unlikely that noscapine represents a genetic risk for humans at therapeutic dosages.
Division of Toxicology, ENEA CRE Casaccia, Roma, Italy.
C
C
Tiveron
B
B
Hartley-Asp
C J
CJ
Johansson
F
F
Pacchierotti
D000782:Aneuploidy; D000818:Animals; D005260:Female; D006801:Humans; D008540:Meiosis / Q000187:drug effects; D051379:Mice; D009665:Noscapine / Q000097:blood / Q000493:pharmacokinetics / Q000633:toxicity*; D009865:Oocytes / Q000187:drug effects* / Q000648:ultrastructure; D011123:Polyploidy; D013045:Species Specificity
D009665:Noscapine